Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers

Leap’s DKN-01 Enters Testing in Metastatic Castration-resistant Prostate Cancers
Leap Therapeutics is launching a Phase 1/2 trial to study its lead candidate DKN-01, alone or in combination with chemotherapy, for the treatment of metastatic castration-resistant prostate cancer (CRPC) patients whose tumors have elevated Dickkopf-1 (DKK1) levels. The trial (NCT03837353), led by David Wise, MD, PhD, will be conducted at the Perlmutter Cancer Center at NYU Langone Health and is expected to begin around the end of March. "Patients with this type of prostate cancer have a very poor prognosis and may benefit from this new immunotherapy strategy targeting DKK1 therapy with DKN-01," Wise said in a press release. The DKK1 protein is often elevated in cancers, leading to more aggressive tumors, poor immune responses, and worse outcomes. The protein plays an important role in controlling the Wnt signaling pathway, a key player during embryonic development that regulates crucial aspects of cell fate and proliferation. Aberrant Wnt activity enables cancer cells to grow uncontrolled and creates an immunosuppressive environment surrounding tumors. Thus, DKK1 inhibition might have a dual anti-cancer mechanism, causing cancer cell death directly and boosting the immune system to fight cancers. Con
Subscribe or to access all post and page content.

Tagged , , , , .

Patricia holds a Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She has also served as a PhD student research assistant at the Department of Microbiology & Immunology, Columbia University, New York.

Leave a Comment

Your email address will not be published. Required fields are marked *